Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Luye Enrolls Last Patient in Phase III Trial of Eylea Biosimilar

publication date: Mar 13, 2023

Yantai-based Luye Pharma has completed enrollment in a China Phase III clinical trial of BA9101, a VEGFR inhibitor that is a biosimilar to Regeneron’s Eylea. Eylea is approved in the US to treat several ophthalmic indications, including Neovascular (Wet) Age-Related Macular Degeneration (wAMD). Luye’s subsidiary, Boan Biotech, is running the trial together with its partner, Shanghai’s Ocumension, which acquired China commercialization rights to the drug. In a Phase I trial, BA9101 proved to be safe and well-tolerated. Luye paid $205 million in 2019 to acquire Boan and its portfolio of eight biosimilar candidates. More details....

Stock Symbol: (HK: 2186) (HK: 6955) (HK: 1477)

Share this with colleagues: